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Abstract:  
The recent demonstration of a role of E. coli in the development of invasive carcinoma 
in mice ushers a new era of bacterial involvement in cancer etiology. It has been shown 
previously that the colonic mucosa of colorectal carcinoma (CRC) is exclusively 
colonized by intracellular E. coli instead of extracellular form found in normal colonic 
mucosa. Surprisingly, the DNA repair gene MUTYH, which is a homologue of the E. 
coli gene mutY, is responsible for CRC. The current paper discusses the potential role 
of mutY in CRC etiology and concludes that research in this area can bring together the 
diverse threads of the CRC etiology puzzle. 
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1. Introduction  
The enigmatic relationship of E. coli with colorectal cancer (CRC) has always raised 
suspicions for cancer researchers in the role of this bacterium in cancer development. 
Recently, an article published in the August 2012 issue of Science revealed that E. coli has 
the capability to promote invasive carcinoma in mice [1]. Although verification of its 
etiological potential in humans is still awaiting a legitimate appraisal, a logical mechanistic 
explanation for this association has been provided through chronic inflammation. Induction 
of proinflammatory cytokines and highly reactive chemical species during chronic 
inflammation leads to oxidation, nitration and chlorination of DNA, RNA and proteins. [2]. 
Khan et al suggested that the frequent association of E. coli with CRC may allow the bacteria 
to serve as an indicator of cancer development [3]. E. coli infection is involved in chronic 
inflammation of the intestine during inflammatory bowel disease (IBD). It has been observed 
that the pathogenesis of IBD involves a consistent increase in mucosa-associated E. coli with 
an "adherent and invasive" phenotype. Although many other bacterial species are also 
involved in IBD [4], the recent demonstration of E. coli induced carcinogenesis in mice 
attracts our attention towards this organism as a possible CRC etiologic agent in humans. 
Two forms of IBD, including Crohn’s disease (CD) and ulcerative colitis (UC), are 
associated with an increased risk in the development of colon cancer [5,6].  
2. E. coli: a host cell cycle modulator 
Several studies have considered the potential role of microbes in CRC etiology [7,8]. A role 
for E. coli in CRC etiology gained much interest after finding mounting evidence for this 
association [9]. It has been verified in many studies that E. coli has an enormous potential for 
cell cycle modulation, thus increasing the chances for the development of cancer. Some E. 
coli strains produce cyclomodulins which interfere with the host cell cycle and may serve as a 
possible link for the association with E. coli and CRC [10]. In addition, cytotoxic necrotizing 
factor (CNF) is a cyclomodulin produced by E. coli; CNF activates rho GTP binding protein 
and prevents apoptosis. CNF modulates both mitochondrial homeostasis and the expression 
of Bcl-2 member of apoptotic regulators. It acts as an apoptosis inhibitor and cell cycle 
stimulator due to the induction of DNA replication and G1/S transition [11-13]. Another E. 
coli cyclomodulin, known as cycle inhibiting factor (Cif), has the ability to cause irreversible 
arrest of the cell cycle at the G2/M transition [14]. Cif, which is produced by 
enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) E. coli strains [15], activates 
G2/M arrest by activating a DNA damage independent pathway through sustained inhibitory 
phosphorylation of mitosis inducer CDK1 [14]. Cif also causes unique alterations in the actin 
cytoskeleton leading to its anchoring to the host cell membrane and cellular and nuclear 
enlargement. Nuclear enlargement occurs due to continuous DNA replication in the absence 
of nuclear division [16]. This endoreduplication increases cellular DNA content and also 
increases gene copy number and proteins including growth factors leading to rapid growth of 
cells and possibly cancer [13,17,18]. Moreover, E. coli also produces cytolethal distending 
toxin (CDT), which causes cell cycle arrest by inflicting DNA damage [19,20]. CDT is a 
tripartite complex with the CdtB subunit homologous to human DNAse I [21]. The role of 
CDT in the carcinogenic process has been investigated in a microbial induced 
hepatocarcinogenesis mouse model. In this model it was observed that Helicobacter 
hepaticus CDT promoted the development of dysplasia from hepatitis and increased 
proliferation of hepatocytes [22].  
It has been reported recently that host cell mismatch repair activity of E. coli infected cells is 
reduced in colon cancer cell lines as well as CRC patients [23]. A reduction of DNA repair 
activity is directly related to an accumulation of mutations and is a suspected reason for E. 
coli driven cancer. Besides these attributes of cell metabolism in E. coli induced cancer 
etiology, this bacteria have little or no capacity for the conversion of N-hydroxy-4-acetyl-
aminobiphenyl (N-OH-AABP) to 4-acetylaminobiphenyl, which reverses activation of the 
parent carcinogen in the gut [24]. It has been known for some time that the gut microflora 
have the capacity to convert several carcinogens to harmless products in the intestine and thus 
minimize the cancer risk [25]. However, during IBD E. coli is generally present as a 
prominent organism and can reduce this attribute of the gut microflora. Although many 
pieces of evidence support a proposed carcinogenic activity of E. coli, a satisfactory 
consensus cannot be achieved on any single mechanism. This situation demands the detection 
of firm evidence and the identification of specific mechanism for the E. coli-CRC 
association.    
3. E. coli and CRC: a peculiar association 
In addition to the mechanistic link between chronic inflammation and CRC development, it is 
also worthy of note that the colorectal carcinoma mucosa, but not normal colonic mucosa, is 
colonised by intracellular E. coli [26]. Chronic inflammation and consequent tissue damage 
induces a cascade of pro-inflammatory and anti-inflammatory molecules. The equilibrium 
between these two groups of regulators controls cell death and repair of tissue damage caused 
due to cell death. However, any problems with this equilibrium may lead to the development 
of cancer [27]. Cellular mutations are additional factors in regulating the development of 
CRC. Several cellular mutations have been identified as etiologic factors for colon cancer and 
these have been reviewed in many recent articles [28]. Among the mutations linked to CRC, 
MUTYH, which encodes for DNA glycosylase, is one of a number of genes involved in 
regulating oxidative DNA damage repair [29]. Although germ line mutations in MUTYH are 
linked to hereditary CRC, somatic mutations in this gene are also associated with cases of 
CRC [30]. It is noteworthy that the cellular MUTYH gene is a homologue of the E. coli gene 
mutY, which is also responsible for regulating DNA damage repair [29]. Thus it offers an 
additional target for investigating the E. coli-CRC association.   
4. Possible role for the involvement of mutY in CRC etiology 
Considering the diverse lines of evidence described above for the microbial etiology of CRC, 
it is interesting to consider a potential role for the E. coli mutY gene in the development of 
colon cancer. E. coli can exist as a chronic intracellular pathogen in colon cells and this 
intimate association between the bacteria and colon cells provides an opportunity for the 
bacteria to grow for many generations and for the old bacterial cells to release their contents 
into the colon cell cytoplasm. Thus, we can speculate that the intracellular E. coli will release 
their DNA and mutY gene products into the colon cell.  
This hypothesis raises three interesting questions. First, due to the high degree of homology 
between mutY and MUTYH, can horizontal gene transfer (HGT) events take place, which 
might affect DNA glycosylase performance? Second, can mutY gene products interfere with 
the activity of human MUTYH gene products? Third, do epigenetic factors that regulate mutY 
gene expression also influence MUTYH expression? Although remote, each of these three 
events could lead to an abnormal DNA repair pathway and ultimately promote the 
development of colon cancer (Figure 1).  
4.1 Horizontal gene transfer of mutY and CRC 
Indirect support for the involvement of HGT in CRC progression comes from the 
demonstration of extensive horizontal gene transfer from intracellular bacterial pathogens to 
their multi-cellular eukaryotic hosts. For example the intracellular bacterial endosymbiont, 
Wolbachia pipientis, has the ability to transfer genes horizontally to its host [31]. The 
intracellular residence of E. coli within colon cells during CRC may thus lead to a similar 
horizontal gene transfer [26]. Furthermore, several bacteria, particularly intracellular bacterial 
pathogens, can influence host metabolism and gene expression in order to sustain them within 
the host cellular environment. Several reports have been published on the subversion of host 
cellular responses by intracellular pathogens [32]. There is some skepticism about the transfer 
of genetic material between intracellular bacteria and the eukaryotic host cell due to the 
physical barriers that exist between the intracellular bacterium and host cell. However, in one 
comparative genomic study approximately 40 genes were identified that were consistent with 
lateral transfer between bacteria and humans [31]. During intracellular bacterial infection, the 
bacterial DNA acts as a symbiotic DNA molecule similar to mitochondrial or chloroplast 
DNA. It is reasonable to propose that these bacterial DNA fragments can affect the host 
MUTYH through horizontal gene transfer (HGT). The mechanism of HGT from bacteria in 
cancer etiology has been reviewed in a recent article [32]. However, it can be argued that 
MUTYH mutations are generally bi-allelic whereas E. coli induced events lead primarily to 
mono-allelic mutations. It is relevant to note that bi-allelic mutations are 10 times more prone 
to result in CRC compared to mono allelic mutations. Thus, bi- and mono-allelic mutations 
could be responsible for early and delayed onset cancers respectively [33]. 
4.2 Direct effects of mutY protein or its epigenetic regulators and CRC 
Due to the high degree of homology between the bacterial mutY and eukaryotic MUTYH 
genes, both functional and structural analogies between the gene products are likely. It has 
been observed previously that the same enzymes from different organisms can differ in their 
degree of substrate specificity. This phenomenon is evident even for equivalent enzymes 
isolated from different bacteria. In the case of the equivalent enzyme from humans and E. 
coli, which are evolutionary distant, it is reasonable to propose that the presence of both 
enzymes in the same cell at one time can interfere with each other’s activity. This latter 
scenario raises the possibility that DNA repair can be impaired, allowing the accumulation of 
mutations that ultimately lead to CRC. As discussed earlier, E. coli has the ability to reduce 
host cell DNA mismatch repair (MMR) in colonic cell lines and this has also been observed 
in CRC patients. This process has been suggested as a possible mechanism for E. coli 
induced colon carcinogenesis [23]. Enteropathogenic E. coli (EPEC) has been shown to 
secrete an effector protein (EspF), which is responsible for the reduction of MMR proteins 
[34]. However, the role of mutY in reducing the DNA repair activity of E. coli infected 
eukaryotic cells also requires a detailed appraisal.   
It is relevant to note that microbes posses the ability to carry out epigenetic alterations of their 
host eukaryotic cells and induce pathological changes through epigenetic reprogramming 
[35]. Epigenetic changes leading to cancer include DNA methylation, histone modification 
and modulation of micro RNA expression [36,37]. Consequently, based on their sequence 
homology, mutY and MUTYH could share similar epigenetic regulators and thus cause 
comparable epigenetic alterations in the host cell DNA repair machinery. Micro RNAs are 
small RNA molecules involved in translation inhibition and silencing of many genes 
including those responsible for cell proliferation, differentiation and cell death. Gut 
microbiota have the capacity to modulate micro RNA expression thus influencing several 
biological processes in the host cell as recently reviewed by Masotti [38]. E. coli is a gram 
negative bacterium within the gut microbiota and has the potential to modulate the expression 
of micro RNA through it lipopolysaccharide (LPS). In macrophages, the LPS of gram 
negative bacteria can induce the expression of mir-155 but down regulate the expression of 
mir-125b micro RNAs [39]. The resident colonic microflora is responsible for the production 
of short chain fatty acids (SCFA) through fermentation of non digestible carbohydrates; these 
SCFAs include butyrate that is an inhibitor of histone deacetylase enzyme and can affect 
histone modification and DNA methylation [40,41]. DNA methylation is known to affect the 
expression of several cancer associated genes [42]. Since the pattern of DNA methylation 
varies between different organisms, it is possible that the presence of E. coli epigenetic 
regulators can lead to reprogramming thus altering the expression of host cell genes including 
MUTYH. Altered patterns of DNA methylation is a common molecular alteration observed 
in human cancers including CRC [43]. This scenario has already been described during 
epigenetic reprogramming of host genes by viruses and intracellular bacteria [44]. 
It is well-documented that enteropathogenic E. coli (EPEC) synthesise a variety of effector 
molecules that are capable of influencing cellular DNA repair [34]. The cytosolic localization 
of E. coli within colon cancer cells allows the bacteria to release the effector molecules 
directly into the host cell cytoplasm, although to affect host cellular processes these bacterial 
effector molecules must enter in the host cell nucleus. E. coli generally uses a Type III 
Secretion System (T3SS) to transfer the bacterial effector molecules into the eukaryotic host 
cell. However, when the bacteria are residing intracellularly the nuclear localization of the 
bacterial proteins depends upon the presence of nuclear localization signals (NLS) on the 
bacterial proteins [45]. Nuclear localization signals are required for the active transport of 
proteins from the cytoplasm to nucleus, although proteins with molecular weights < 40 kDa 
can transfer to the nucleus via a passive transport mechanism [45,46]. Surprisingly, the mutY 
protein (NCBI Accession number EGT70329) has a molecular weight of 39.18 kDa giving 
strong support for its nuclear localization via the passive transport mechanism. Similar to the 
possible mutY nuclear transport, the epigenetic regulators have a high propensity for an 
intracellular localization due to functional relatedness. For example, E. coli replication 
terminator protein Tus, an E. coli epigenetic regulator, has both a NLS and nuclear export 
signal (NES), and can therefore target the host cell nucleus. Although research in this area is 
in the early days, Tus protein was one of the first proteins shown to possess both NLS and 
NES, thus supporting a role in epigenetic targeting of the host cell nucleus [47]. However, 
future research on bacterial epigenetic regulators will, no doubt, identify similar host nuclear 
targeting potential for many E. coli proteins, perhaps including mutY. Therefore, chronic E. 
coli infection may create a situation where chronic inflammation, caused by the E. coli 
infection, leads to mutY mediated cellular alterations in the host cell DNA repair machinery 
that controls the development of CRC.  
5. Concluding remarks 
Our current understanding of CRC pathogenesis raises suspicion for a potential role of E. coli 
mutY in colon cancer and research in this direction is uncovering several aspects of CRC 
pathogenesis. Further research is required to address the potential role of E. coli in colon 
cancer development. Several aspects of the proposal outlined above, specifically the 
intracellular growth of E. coli in colon cancer cells, the homology between the mutY and 
MUTYH genes, possible horizontal gene transfer from the intracellular E. coli during colon 
cancer, and the presence of mutY and MUTYH gene products in same cell provide clues for 
linking these threads. Further research will provide new avenues to understand CRC etiology 
and help us to plan and implement infection control measures to control CRC. Managing an 
infection is much easier than managing the cancer itself; hence the role of E. coli mutY in 
CRC should be investigated further.    
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Figure 1: Proposed explanation for the potential involvement of E. coli mutY in CRC etiology. During chronic E. coli infection, the bacteria establish an intracellular residence of bacteria in associated colon cancer cells. (A) Shedding of the bacterial DNA into the host cell and due to sequence homology between mutY and MUTYH, horizontal gene transfer events may occur, which can lead to the development of CRC. (B) Products of 
E. coli mutY and human MUTYH can also affect the ability of DNA repair in host cell (C) Epigenetic regulators of the bacterial mutY gene can also affect human MUTYH leading to abnormal expression of MUTYH and ultimately the development of CRC. 
 
